Menstrual Relief

Product NDC
11673-084
11-digit product format
116730084
Labeler code
11673
Product ID
11673-084_919f4da9-3d20-4a88-987f-d1baba132c29
Type
HUMAN OTC DRUG
Nonproprietary name
Acetaminophen, Caffeine and Pyrilamine maleate
Dosage form
TABLET
Route
ORAL
Labeler
TARGET Corporation
Application
part343
Marketing category
OTC MONOGRAPH NOT FINAL
Marketing start
2014-12-31
Marketing end
2020-12-31
Substance
ACETAMINOPHEN; CAFFEINE; PYRILAMINE MALEATE
Active strength
500 mg/1; mg/1; mg/1
NDC exclude flag
No
Listing certified through
0000-00-00
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct11673-084DDiscontinued by firm2026-10-16
excluded packagepackage11673-08411673-084-40DDiscontinued by firm2026-10-16

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 24 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source dateDatasetScopePackage NDCSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05excluded productproductd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage11673-084-40d630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26excluded productproductf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage11673-084-40f5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-31excluded productproduct2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage11673-084-402ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28excluded productproducta1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage11673-084-40a1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21excluded productproductcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage11673-084-40cfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10excluded productproductcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage11673-084-40cdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31excluded productproduct302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage11673-084-40302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20excluded productproducted331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage11673-084-40ed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-10excluded productproduct0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage11673-084-400efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08excluded productproductad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage11673-084-40ad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03excluded productproduct367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage11673-084-40367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09excluded productproduct557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage11673-084-40557ba5c1ecfa…9c80585c8c6e…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
ACETAMINOPHENACTIVE INGREDIENT362O9ITL9DMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
CAFFEINEACTIVE INGREDIENT3G6A5W338EMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
PYRILAMINE MALEATEACTIVE INGREDIENTR35D29L3ZAMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
ACETAMINOPHENACTIVE MOIETY362O9ITL9DMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
CAFFEINEACTIVE MOIETY3G6A5W338EMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
PYRILAMINEACTIVE MOIETYHPE317O9TLMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61UMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
CROSCARMELLOSE SODIUMINACTIVE INGREDIENTM28OL1HH48MENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
CROSPOVIDONE (15 MPA.S AT 5%)INACTIVE INGREDIENT68401960MKMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
HYPROMELLOSESINACTIVE INGREDIENT3NXW29V3WOMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I30MENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
MINERAL OILINACTIVE INGREDIENTT5L8T28FGPMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
POVIDONESINACTIVE INGREDIENTFZ989GH94EMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU4MENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
STARCH, CORNINACTIVE INGREDIENTO8232NY3SJMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65APMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JPMENSTRUAL RELIEF MAXIMUM STRENGTH (ACETAMINOPHEN, CAFFEINE AND PYRILAMINE MALEATE) TABLET [TARGET CORPORATION]3